Role of Circulating Serum Apelin-13 Levels in Glomerulonephritis: A Pilot Study

Yasemin Coskun Yavuz1*, Can Sevinc1, Mustafa Saygin Deniz2, Serkan Yavuz2, Orcun Altunoren2, Ahmet Celik2, Recep Demirci3, Hayriye Sayarlioglu4 and Ekrem Dogan5

1Erzurum Regional Research and Training Hospital, Internal Medicine, Department of Nephrology, Erzurum, Turkey
2Kahramanmaras Sutcu Imam University, Department of Internal Medicine, Kahramanmaras, Turkey
3Kanuni Sultan Suleyman Research and Training Hospital, Internal Medicine, Department of Nephrology, Istanbul, Turkey
4Ondokuz Mayis University, Internal Medicine, Department of Nephrology, Samsun, Turkey
5Selahattin Eyyubi University, Internal Medicine, Department of Nephrology, Diyarbakir, Turkey

*Corresponding author: Yasemin Coskun Yavuz, Erzurum Regional Research and Training Hospital, Department of Nephrology, Erzurum, Turkey, Tel: 904422325307; E-mail: yasemincoskun@yahoo.com

Received date: November 11, 2015; Accepted date: November 16, 2015; Published date: November 23, 2015

Citation: Yavuz YC, Sevinc C, Deniz MS, Yavuz S, Altunoren O, et al. (2015) Role of Circulating Serum Apelin-13 Levels in Glomerulonephritis: A Pilot Study. J Clin Exp Nephrol 1: 2. DOI: 10.21767/2472-5056.100002

Copyright: © 2015 Yavuz YC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Apelin is a new peptide identified as the endogenous ligand of the G protein-coupled receptor, APJ. Apelin-related peptides were first isolated from bovine stomach extracts as soluble factors able to increase extracellular acidification rate and inhibit cAMP production in hamster ovary cells transfected with APJ cDNA [1]. Apelin is secreted from brain, placenta, lungs, heart, kidneys also from the veins of coronary artery, saphenous vein, kidneys and adrenal gland [2]. Apelin is secreted as preproapelin, that has the sequence of 77 amino acids, preproapelin is then fragmented by protease and apelin will be named as Apelin-13, Apelin-17 and Apelin-36, depending on the number of amino acids it contains. Apelin-36 and apelin-13 represent the predominant and most active isoforms. Apelins show effect with the different affinity attachments to apelin (APJ) receptor. APJ receptor is found in 1993 for the first time, and named as angiotensin-II receptor-like 1 (AGTRL1) due to the resemblance to Angiotensin II type 1 [3,4]. That apelin has a beneficial effect of on renal disease is also suggested by several studies. For example, apelin has been found to lower blood pressure in the two-kidney-one-clip hypertension rat model through its effect on vascular relaxation [5]. Apelin has also been observed to protect cells at a histopathological level in a rat model of renal ischaemia and reperfusion injury [6]. Furthermore, subcutaneous injection of apelin-13 reduces glomerular hypertrophy and renal inflammation in Ove26 mice, a model of type 1 diabetes. Also, reduced proteinuria is observed with injected apelin in rats with caused diabetic nephropathy [7]. However, the mechanisms by which apelin-13 protects against renal diseases are still unclear. Also in several studies, it was found that the association between proteinuria and nephrotic syndrome with renal tissue levels of apelin-13, but there is no clinical studies that have measured the levels of serum apelin-13 in glomerulonephritis. In this study we aim to
observe the circulating serum apelin-13 levels in patients with glomerulonephritis by comparing with healthy subjects.

Materials and Methods

The study protocol was approved by the Kahramanmaras Sutcu Imam University Local Ethics Committee (protocol 1205/14). 53 glomerulonephritis patients that were newly diagnosed and under continuing treatment was used in our study. Demographic data and the levels of creatinine, albumin, urinalysis and spot urine protein/creatinine ratios of these patients were recorded from hospital information file system. The patients’ BMI values were calculated using the formula weight (kg)/height (m)². Body surface area was calculated using the formula 0.007184 × height (cm)⁰.⁷²⁵ × weight (kg)⁰.⁴²⁵. Blood pressure was measured using a calibrated aneroid sphygmomanometer that had a cuff width and balloon diameter suitable for each patient, in accordance with the World Health Organization’s (WHO) measurement criteria. Patients’ body mass indexes and arterial blood pressures were measured and recorded. 54 healthy individuals was taken to the study as a control group. As a control group; without acute or chronic disease known, non-regular drug use history for any reason, patients who had hypertension and 40 patients did not. 40 (75.5%) of 53 patients were receiving nonimmunosuppressive treatment. 32 of 53 patients had been received nonimmunosuppressive treatment. 13 patients showed no proteinuria in urine analysis, 6 patients had trace amount of proteinuria. 9 patients showed +1 and 23 patients showed +3 proteinuria. The most common 3 reasons, that were shown in the tissue analysis, were IgA nephropathy for 16 patients, membranous glomerulonephritis (MGN) for 10 patients and membranoproliferative glomerulonephritis (MPGN) for 9 patients. Apelin-13 levels were compared between the group of patients and control group. Average apelin-13 level was 1863 ± 1783 pg/ml for patient group and average apelin-13 was 2392 ± 1846 pg/ml for control group. A significant difference between the groups had not been seen (p=0.13)(Table 2). Apelin levels between the glomerulonephritis patients with proteinuria and glomerulonephritis patients without proteinuria were compared for any differences. Patients with proteinuria had 1784 ± 1756 pg/ml and patients without proteinuria had 2274 ± 1896 pg/ml apelin-13 (p=0.43). The correlation between protein/creatinine ratio and apelin-13 level was checked via spot urine analysis in patient group of glomerulonephritis, there was no significant correlation (p=0.83, r=0.15). Also there was no significant correlation between apelin-13 levels and BMI (p=0.26, r=0.131), weight (p=0.28, r=0.198), albumin levels (p=0.66, r=0.212) in the patient group. Apelin-13 levels were compared between immunosuppressive treated (average 1828 ± 1798 pg/ml) and untreated patients (average 1918 ± 1802 pg/ml). Apelin-13 levels were not significantly different between in two groups (p=0.85).

Table 1: The demographic values of the patient and control group.

| Age (years) | Patients (n=53) | Control (n=54) | p-value |
|-------------|----------------|---------------|---------|
| 36.1 ± 16.9 | 40.7 ± 13.6    | 0.39          |
| Gender (M/F)| 31/22          | 18/36         |         |
| BMI (kg/m²) | 27.5 ± 5.3     | 27.4 ± 5.4    |         |
| MAP (mmHg)  | 90.6 ± 6       | 90.9 ± 5.9    | 0.09    |
| Creatinine (mg/dl) | 1.1 ± 0.6     | 0.67 ± 0.13   |         |
| Albumin (gr/dl) | 4.05 ± 0.6    | 4.5 ± 0.2     | <0.001  |

BMI: Body Mass Index; MAP: Mean Arterial Pressure

Table 2: The Apelin-13 levels of patients and control group.
The distribution of apelin and apelin receptor APJ has been found in kidneys along with most tissues [1]. Intermediate level of preproapelin has been found in kidney, heart, lungs and mammal gland, mostly preproapelin is seen in central nerve system and placenta [9]. Apelin receptor API is shown to be expressed in the kidneys of rats and human. ApJ receptor expression has been found mostly at the inside of outer medulla along vasa recta and leastly at outside of outer medulla and cortex [10]. Increased Apelin and APJ mRNA levels are observed in the rats, that are unilateral fibrosis caused by ureteral obstruction [11]. Increased apelin levels are found along glomerular basal membrane in the rats with adriamycin induced nephrotic syndrome [7]. Decreased API receptor levels are observed upon deliver of the apelin in glomeruli and kidney veins of the rats with diabetic nephropathy [12]. The effect of Apelin API system on tissue fibrosis and progression is shown at liver fibrosis [13]. The effect of Apelin API system is shown to result in decrease of fibrosis against angiotensin 2 at heart and kidney fibrosis [14]. Rats formed renal fibrosis with one tied ureter, the decreased effect of ARB on fibrosis has been found to be increased with apelin API system and shown as increased levels in the side with tied ureter. All antifibrotic effect of ARBs are observed to be decreased with the deliver of antagonist of API receptor. These results are thought to be a hope for decreasing fibrosis with apelin like RAAS inhibitors [10,11]. A study with rats formed diabetic nephropathy, upon delivery of apelin-13; no significant change in the weight and serum glucose levels; decreased glomerular hypertension, no significant change in albuminuria for the first 3 months but at the end of 6 months with the injection of apelin-13 significant decrease in albuminuria has been observed. Also; reduced activation of ang-II, AT1 receptor with apelin has not been observed. Therefore, it has been thought antioxidant system activation is the reason for reduced proteinuria. In pathologic examinations, the number of podocytes has remained the same but reduced proteinuria via epithelial cells of the proximal tubule are found [15]. Unlike the existing studies we investigated the serum apelin-13 levels in glomerulonephritis, not in the renal tissue. In our study, serum apelin-13 levels showed no significant difference between the patients with glomerulonephritis and healthy control group. We did not find such a study in the literature about association between serum apelin-13 levels and glomerulonephritis. Also unlike the present studies we couldn’t find a significant correlation between serum apelin-13 levels with proteinuria. In addition, in patients with glomerulonephritis we did not find significant differences in serum apelin-13 levels between among those taking the immunosuppressive therapy and not taking. In animal experiments, apelin is found increased at fibrosis formed kidneys and also increased apelin is seen along glomerular basal membrane in rats with nephrotic syndrome. If we had done renal biopsy, we could have found a different apelin level in tissues between glomerulonephritis patients and control group but in the serum we did not see a significant difference. Due to the fact of ethical reasons, it seems hard to make a clinical study with renal biopsy in control group. On the other hand, the low number of patients in our study may have affected the results. For now, as a conclusion; there was no significant difference between glomerulonephritis patients and control group in our study.

| Apelin (pg/ml) | Patient | Control | p-value |
|---------------|---------|---------|---------|
| 1863 ± 1783   | 2392 ± 1846 | 0.13    |

**References**

1. **Boucher** (2005) Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology 146: 1764-1771.
2. **Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, et al.** (2001) Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 1538: 162-171.
3. **Foldes G, Horkay F, Szokodi I, Vuoletenaho O, Ilves M, et al.** (2003) Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor API, in patients with heart failure. Biochem Biophys Res Commun 308: 480-485.
4. **Kälén RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, et al.** (2007) Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 305: 599-614.
5. **Soltani Hekmat A, Najafipour H, Nekooian AA, Esmæli-Mahan S, Javanmardi K** (2011) Cardiovascular responses to apelin in two-kidney-one-clip hypertensive rats and its receptor expression in ischemic and non-ischemic kidneys. Regul Pept 172: 62-68.
6. **Sagirolgu T, Torun N, Yakci M, Yalta T, Sagirolgu G, et al.** (2012) Effects of apelin and leptin on renal functions following renal ischemia/reperfusion: An experimental study. Exp Ther Med 3: 908-914.
7. **Day RT, Cavaglieri RC, Feliers D** (2013) Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol 304: 788-800.
8. **O’Dowd BF, Heiber M, Chan A, Heng H, Tsui LC, et al.** (1993) A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136: 355-360.
9. **Castan-Laurell I, Boucher J, Dray C, Daviaud D, Guigné C, et al.** (2005) Apelin, a novel adipokine over-produced in obesity: Friend or foe? Molecular and Cellular Endocrinology 245: 7-9.
10. **Hus-Citharel A, Bouby N, Frugière A, Bodineau L, Gasc JM, et al.** (2008) Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int 74: 486-494.
11. **Nishida M, Okumura Y, Oka T, Toiyama K, Ozawa S, et al.** (2012) The role of apelin on the alleviative effect of angiotensin receptor blocker in unilateral ureteral obstruction-induced renal fibrosis. Nephron Extra 2: 39-47.
12. **Bo Y, Yuan L** (2012) Glomerular expression of apelin and its association with proteinuria. Indian J Pediatr 79: 1028-1032.
13. **Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T** (2010) Effects of olmesartan on Apelin/APJ and Akt/eNOS pathway in Dahl rats with end-stage heart failure. J Cardiovasc Pharmacol 55: 83-88.
14. **Nishida M, Okumura Y, Oka T, Toiyama K, Ozawa S, et al.** (2012) The role of apelin on the alleviative effect of angiotensin receptor blocker in unilateral ureteral obstruction-induced renal fibrosis. Nephron Extra 2: 39-47.
15. Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, et al. (2012) Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 33: 2360-2369.